IXICO (IXI) Competitors

GBX 8.18
+0.06 (+0.68%)
(As of 05/3/2024 01:28 PM ET)

IXI vs. OCTP, EVG, VAL, APTA, FAB, BSFA, PYC, ROQ, NFX, and GENF

Should you be buying IXICO stock or one of its competitors? The main competitors of IXICO include Oxford Cannabinoid Technologies (OCTP), Evgen Pharma (EVG), ValiRx (VAL), Aptamer Group (APTA), Fusion Antibodies (FAB), BSF Enterprise (BSFA), Physiomics (PYC), Roquefort Therapeutics (ROQ), Nuformix (NFX), and Genflow Biosciences (GENF). These companies are all part of the "biotechnology" industry.

IXICO vs.

IXICO (LON:IXI) and Oxford Cannabinoid Technologies (LON:OCTP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, community ranking, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Oxford Cannabinoid Technologies has a net margin of 0.00% compared to IXICO's net margin of -17.67%. IXICO's return on equity of -9.85% beat Oxford Cannabinoid Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-17.67% -9.85% -6.50%
Oxford Cannabinoid Technologies N/A -86.76%-53.92%

IXICO has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Oxford Cannabinoid Technologies has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

56.9% of IXICO shares are owned by institutional investors. Comparatively, 14.1% of Oxford Cannabinoid Technologies shares are owned by institutional investors. 30.4% of IXICO shares are owned by company insiders. Comparatively, 29.8% of Oxford Cannabinoid Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IXICO received 144 more outperform votes than Oxford Cannabinoid Technologies when rated by MarketBeat users.

CompanyUnderperformOutperform
IXICOOutperform Votes
144
71.64%
Underperform Votes
57
28.36%
Oxford Cannabinoid TechnologiesN/AN/A

IXICO has higher revenue and earnings than Oxford Cannabinoid Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£6.67M0.59-£1.18M-£0.02-409.00
Oxford Cannabinoid TechnologiesN/AN/A-£4.24MN/AN/A

In the previous week, IXICO and IXICO both had 1 articles in the media. IXICO's average media sentiment score of 0.67 equaled Oxford Cannabinoid Technologies'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IXICO
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oxford Cannabinoid Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IXICO
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Oxford Cannabinoid Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

IXICO beats Oxford Cannabinoid Technologies on 7 of the 10 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IXI vs. The Competition

MetricIXICOBiotechnology IndustryMedical SectorLON Exchange
Market Cap£3.96M£161.94M£5.09B£1.61B
Dividend Yield1.27%3.55%2.88%6.36%
P/E Ratio-409.00207.22242.801,969.23
Price / Sales0.5915,963.612,431.01424,485.03
Price / Cash2.2511.5448.7336.17
Price / Book0.345.884.862.42
Net Income-£1.18M-£20.07M£103.66M£178.24M
7 Day Performance-5.16%3.21%3.91%0.88%
1 Month Performance-5.16%0.84%-3.19%7.41%
1 Year Performance-57.51%-0.77%5.70%14.26%

IXICO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCTP
Oxford Cannabinoid Technologies
0 of 5 stars
GBX 0.37
+2.8%
N/A-73.4%£4.03MN/A-53.107Gap Up
EVG
Evgen Pharma
0 of 5 stars
GBX 0.80
flat
N/A-77.8%£3.42MN/A-80.0010Gap Up
VAL
ValiRx
0 of 5 stars
GBX 3.37
+2.1%
N/A-67.0%£4.46MN/A-112.338
APTA
Aptamer Group
0 of 5 stars
GBX 0.68
-6.9%
N/A-97.6%£3.16M£1.03M-8.4437Gap Down
FAB
Fusion Antibodies
0 of 5 stars
GBX 3.28
+1.7%
N/A-92.3%£3.13M£1.58M-36.4448News Coverage
Gap Down
BSFA
BSF Enterprise
0 of 5 stars
GBX 4.98
-0.5%
N/A-65.9%£5.14MN/A-248.7512Gap Down
PYC
Physiomics
0 of 5 stars
GBX 1.57
+1.0%
N/A-56.7%£2.12M£900,707.00-13.8310News Coverage
Gap Down
ROQ
Roquefort Therapeutics
0 of 5 stars
GBX 4.50
+2.3%
N/A-36.3%£5.81M£637.00-381.259Gap Down
NFX
Nuformix
0 of 5 stars
GBX 0.18
-3.2%
N/A-22.2%£1.51M£50,000.00-1.633Gap Down
High Trading Volume
GENF
Genflow Biosciences
0 of 5 stars
GBX 2.05
+2.5%
N/AN/A£7.17MN/A-256.005Gap Up

Related Companies and Tools

This page (LON:IXI) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners